Becton Dickinson and Company
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Becton Dickinson and Company (BDX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Medical Essentials | $1.59B 30.7% | $1.57B 35.1% | $1.60B 33.9% | $1.60B 30.4% | $1.65B 34.9% · +3.8% | $1.68B 33.6% · +6.5% |
| Interventional | $1.26B 24.3% | $1.26B 28.2% | $1.33B 28.1% | $1.33B 25.3% | $1.36B 28.8% · +8.0% | $1.41B 28.4% · +11.9% |
| Connected Care | $1.07B 20.8% | $1.07B 23.8% | $1.17B 24.7% | $1.13B 21.5% | $1.12B 23.8% · +4.4% | $1.22B 24.6% · +14.6% |
| BioPharma Systems | $418.0M 8.1% | $575.0M 12.8% | $629.0M 13.3% | $429.0M 8.2% | $590.0M 12.5% · +41.1% | $670.0M 13.4% · +16.5% |
| Life Sciences | $836.0M 16.2% | – | – | $766.0M 14.6% | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Medical Essentials | $607.0M 38.3% | $617.0M 39.2% | $612.0M 38.2% | $569.0M 35.7% | $574.0M 34.9% | $617.0M 36.8% |
| Interventional | $561.0M 44.6% | $565.0M 44.7% | $549.0M 41.3% | $561.0M 42.2% | $579.0M 42.7% | $565.0M 40.0% |
| Connected Care | $336.0M 31.3% | $353.0M 33.1% | $417.0M 35.8% | $352.0M 31.1% | $347.0M 31.0% | $395.0M 32.3% |
| BioPharma Systems | $141.0M 33.7% | $224.0M 39.0% | $239.0M 38.0% | $140.0M 32.6% | $225.0M 38.1% | $259.0M 38.7% |
| Life Sciences | $240.0M 28.7% | – | – | $159.0M 20.8% | – | – |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by region
| Segment | Q4 2024 | Q1 2025 | Q2 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| UNITED STATES | $3.08B 59.6% | $2.78B 62.0% | $2.88B 61.0% | $3.16B 60.1% | $2.92B 61.9% · -5.3% | $3.08B 61.8% · +11.0% |
| International | $2.09B 40.4% | $1.70B 38.0% | $1.84B 39.0% | $2.09B 39.9% | $1.80B 38.1% · -14.0% | $1.90B 38.2% · +11.6% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.